DK2423216T3 - Replikationskompetent hepatitis C-virus og fremgangsmåder til anvendelse - Google Patents

Replikationskompetent hepatitis C-virus og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK2423216T3
DK2423216T3 DK11005809.6T DK11005809T DK2423216T3 DK 2423216 T3 DK2423216 T3 DK 2423216T3 DK 11005809 T DK11005809 T DK 11005809T DK 2423216 T3 DK2423216 T3 DK 2423216T3
Authority
DK
Denmark
Prior art keywords
leu
ala
gly
val
thr
Prior art date
Application number
DK11005809.6T
Other languages
English (en)
Inventor
Stanley M Lemon
Minkyung Yi
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK2423216T3 publication Critical patent/DK2423216T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (14)

1. Replikationskompetent polynukleotid omfattende: en 5'-ikke-translateret region (NTR), en 3' NTR, og en kodende sekvens der foreligger mellem 5' NTR og 3' NTR og koder for et hepatitis C-viruspolyprotein, hvor polyproteinet omfatter isoleucin i stedet for serin svarende til serin 2204 ifølge SEQ ID NO:2, og yderligere omfatter arginin i stedet for lysin svarende til lysin 2040 ifølge SEQ ID NO:2, hvor 5' NTR, 3' NTR og nukleotidsekvensen der koder for polyproteinet er genotype la, og hvor polyproteinet omfatter en aminosyresekvens med mindst 90% identitet med SEQ ID NO:2.
2. Replikationskompetent polynukleotid ifølge krav 1, hvor polyproteinet yderligere omfatter en kombination af adaptive mutationer valgt fra gruppen arginin i stedet for glutamin svarende til glutamin 1067 ifølge SEQ NO:2, arginin i stedet for lysin svarende til lysin 1691 ifølge SEQ NO:2, valin i stedet for phenylalanin svarende til phenylalanin 2080 ifølge SEQ NO:2, isoleucin i stedet for valin svarende til valin 1655 ifølge SEQ NO:2, og arginin i stedet for glycin svarende til glycin 1188 ifølge SEQ NO:2.
3. Replikationskompetent polynukleotid ifølge krav 1 endvidere omfattende en yderligere kodende region.
4. Replikationskompetent polynukleotid ifølge krav 3, hvor den yderligere kodende sekvens koder for en markør.
5. Replikationskompetent polynukleotid ifølge krav 3, hvor den yderligere kodende sekvens koder for en transaktivator.
6. Replikationskompetent polynukleotid ifølge krav 1 yderligere omfattende en nukleotidsekvens med cis-aktiv ribozymaktivitet, hvor nukleotidsekvensen er lokaliseret 3' af 3' NTR.
7. Replikationskompetent polynukleotid ifølge krav 1, hvor lokaliseringen afen given aminosyre varierer ved 1 eller 2 eller 3 eller 4 eller 5 rester sammenlignet med placeringen i SEQ ID NO:2.
8. Fremgangsmåde til fremstilling af viruspartikler, omfattende inkubering af en celle omfattende replikationskompetent polynukleotid ifølge krav 1 under betingelser der tillader polynukleotidet at replikere, hvor det replikationskompetente polynukleotid er til stede i viruspartiklerne.
9. Fremgangsmåden ifølge krav 8 yderligere omfattende isolering af viruspartiklerne.
10. Viruspartikler indeholdende replikationskompetent polynukleotid ifølge krav 1.
11. Kit omfattende: et replikationskompetent polynukleotid ifølge krav 1 yderligere omfattende mellem 5' NTR og 3' NTR, en yderligere kodende sekvens der koder for en transaktivator; og en celle omfattende et polynukleotid omfattende en transaktiveret kodende sekvens der koder for en detekterbar markør og en operatorsekvens operabelt bundet til den transaktiverede kodende sekvens, hvor transaktivatoren interagerer med operatorsekvensen og ændrer ekspression af den transaktiverede kodende sekvens.
12. Replikationskompetent polynukleotid ifølge krav 1 eller kittet ifølge krav 11 hvor hepatitis C-viruspolyproteinet er et subgenomisk hepatitis C-viruspolyprotein.
13. Replikationskompetent polynukleotid ifølge krav 1, eller fremgangsmåden ifølge krav 8, eller kittet ifølge krav 11 hvor hepatitis C-virus-polyproteinet omfatter spaltningsproduktkerner, El, E2, P7, NS2, NS3, NS4A, NS4B, NS5A, og NS5B.
14. Fremgangsmåde til at detektere et replikationskompetent polynukleotid, hvilken fremgangsmåde omfatter: inkubere en celle omfattende et replikationskompetent polynukleotid, hvor: det replikationskompetente polynukleotid er et polynukleotid ifølge krav 1 yderligere omfattende mellem 5' NTR og 3' NTR en yderligere kodende sekvens der koder for en transaktivator; cellen omfatter en transaktiveret kodende region og en operatorsekvens operabelt bundet til den transaktiverede kodende region; og den transaktiverede kodende region koder for en detekterbar markør, hvor transaktivatoren ændrer transkription af den transaktiverede kodende region; og detektere den detekterbare markør, hvor tilstedeværelsen af den detekterbare markør indikerer at cellen omfatter et replikationskompetent polynukleotid.
DK11005809.6T 2003-12-01 2004-12-01 Replikationskompetent hepatitis C-virus og fremgangsmåder til anvendelse DK2423216T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52598903P 2003-12-01 2003-12-01
EP04812596A EP1694694B1 (en) 2003-12-01 2004-12-01 Replication competent hepatitis c virus and methods of use

Publications (1)

Publication Number Publication Date
DK2423216T3 true DK2423216T3 (da) 2015-07-20

Family

ID=34652405

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04812596.7T DK1694694T3 (da) 2003-12-01 2004-12-01 Replikationskompetent hepatitis C-virus samt anvendelsesfremgangsmåder
DK11005809.6T DK2423216T3 (da) 2003-12-01 2004-12-01 Replikationskompetent hepatitis C-virus og fremgangsmåder til anvendelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04812596.7T DK1694694T3 (da) 2003-12-01 2004-12-01 Replikationskompetent hepatitis C-virus samt anvendelsesfremgangsmåder

Country Status (5)

Country Link
US (1) US8026092B2 (da)
EP (2) EP2423216B1 (da)
DK (2) DK1694694T3 (da)
ES (1) ES2415106T3 (da)
WO (1) WO2005053516A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921634B2 (en) * 1999-12-23 2005-07-26 Board Of Regents, The University Of Texas System Replication competent hepatitus C virus and methods of use
ES2389201T3 (es) * 2003-10-27 2012-10-24 Vertex Pharmaceuticals Incorporated Mutantes de resistencia de la proteasa NS3/4A de HCV
DK1694694T3 (da) 2003-12-01 2013-05-06 Univ Texas Replikationskompetent hepatitis C-virus samt anvendelsesfremgangsmåder
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
WO2008125119A1 (en) * 2007-04-13 2008-10-23 Hvidovre Hospital Adaptive mutations allow establishment of jfh1-based cell culture systems for hepatitis c virus genotype 4a
WO2008125117A1 (en) * 2007-04-13 2008-10-23 Hvidovre Hospital Cell culture system of a hepatitis c genotype 3a and 2a chimera
CA2692815A1 (en) * 2007-04-27 2008-11-13 Advanced Life Science Institute, Inc. Hcv gene
WO2008141651A1 (en) * 2007-05-18 2008-11-27 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 5a
US8569472B2 (en) 2007-12-20 2013-10-29 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 6A
WO2010017818A1 (en) 2008-08-15 2010-02-18 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 2b
US8506969B2 (en) 2008-08-15 2013-08-13 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 7a
WO2010028999A2 (en) * 2008-09-12 2010-03-18 F. Hoffmann-La Roche Ag Production of infectious hepatitis c virus particles in cell culture
WO2010039649A2 (en) * 2008-10-03 2010-04-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Flavivirus-based system for production of hepatitis c virus (hcv)
EP2344647A1 (en) 2008-10-03 2011-07-20 Hvidovre Hospital Hepatitis c virus expressing reporter tagged ns5a protein
CA2840828A1 (en) * 2011-07-06 2013-01-10 Gilead Sciences, Inc. Hcv genotype 3 replicons
MX2014000123A (es) * 2011-07-06 2014-02-17 Gilead Sciences Inc Replicones de genotipo 4 de hcv.
SG11201501505WA (en) 2012-08-31 2015-03-30 Univ Alberta Methods for producing cells having a phenotype of a primary human hepatocytes and compositions
WO2015179204A1 (en) * 2014-05-19 2015-11-26 The University Of North Carolina At Chapel Hill Replication-competent clones of hepatitis c virus genotype 1a
EP3201342A4 (en) 2014-10-01 2018-07-25 National Research Council of Canada Animal models, cell lines and methods for screening hepatitis c virus vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326271D0 (en) * 1993-12-23 1994-02-23 Zeneca Ltd Expression of self-processing polyprotein in transgenic plants
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
US5912167A (en) * 1995-06-06 1999-06-15 Wisconsin Alumni Research Foundation Autocatalytic cleavage site and use thereof in a protein expression vector
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5874565A (en) * 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
WO2000014263A2 (en) 1998-09-03 2000-03-16 Board Of Regents, The University Of Texas System Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
US20020155582A1 (en) * 1999-12-23 2002-10-24 Lemon Stanley M. Replication competent hepatitis C virus and methods of use
US6921634B2 (en) 1999-12-23 2005-07-26 Board Of Regents, The University Of Texas System Replication competent hepatitus C virus and methods of use
WO2002038793A2 (en) * 2000-11-07 2002-05-16 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
CA2434845C (en) * 2001-01-23 2013-11-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus replicons and replicon enhanced cells
US6689559B2 (en) * 2001-11-29 2004-02-10 The Research Foundation Of The State University Of New York Efficient hepatitis C virus replicon and its use in identifying antiviral compounds
US7416840B2 (en) 2002-12-13 2008-08-26 Fox Chase Cancer Center Replication of hepatitis C virus in non-hepatic epithelial and mouse hepatic cells
DK1694694T3 (da) 2003-12-01 2013-05-06 Univ Texas Replikationskompetent hepatitis C-virus samt anvendelsesfremgangsmåder

Also Published As

Publication number Publication date
EP1694694A4 (en) 2007-07-25
EP1694694B1 (en) 2013-01-23
WO2005053516A2 (en) 2005-06-16
EP2423216A1 (en) 2012-02-29
WO2005053516A3 (en) 2005-12-29
EP1694694A2 (en) 2006-08-30
US20070292840A1 (en) 2007-12-20
US8026092B2 (en) 2011-09-27
ES2415106T3 (es) 2013-07-24
DK1694694T3 (da) 2013-05-06
EP2423216B1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
DK2423216T3 (da) Replikationskompetent hepatitis C-virus og fremgangsmåder til anvendelse
AU770486B2 (en) Hepatitis C virus cell culture system
AU2005275713B2 (en) Modified human hepatitis C virus genomic RNA having autonomous replicative competence
US20040029279A1 (en) Packaging of positive-strand rna virus replicon particles
AU740768B2 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU2003267851B2 (en) Novel full-length genomic RNA of Japanese encephalitis virus, infectious JEV CDNA therefrom, and use thereof
US8367401B2 (en) Replication competent hepatitis C virus and methods of use
CN100475964C (zh) Hcv复制子穿梭载体
CN105176936B (zh) 复制耐受型的西门利克森林病毒的亚克隆及制备方法和应用
CN113355296A (zh) 一种表达人ccl19的重组溶瘤新城疫病毒及其应用
AU2008333339A1 (en) HCV NS3 protease replicon shuttle vectors
CN114874332B (zh) 经修饰的rnf112作为治疗als药物的应用
KR101578444B1 (ko) 구제역 a형 한국분리주를 이용한 재조합 구제역 바이러스 및 그의 제조방법
CN113355288B (zh) 一种治疗covid-19的通用型嵌合抗原受体t细胞的制备方法及应用
CN107058390A (zh) 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用
CA2539457A1 (en) Nucleic acid and gene derived from novel hcv strain and replicon-replicating cell using said gene
CN106520837A (zh) 一种重组载体及其应用
CN113604496A (zh) 利用烟草脆裂病毒同时表达两种外源蛋白的载体构建法
CN111518833B (zh) 一种携带aim2基因的溶瘤腺病毒的构建方法及应用
CN101745107A (zh) 一种重组复制缺陷型腺病毒载体h5n1亚型流感基因工程疫苗
AU701384B2 (en) Expression of heterologous proteins in attenuated bacteria using the htrA-promoters
WO2008148671A1 (en) Hcv ns3 replicon shuttle vectors
EP1493749A1 (en) Novel HCV core + 1 protein, methods for diagnosis of HCV infections, prophylaxis, and for screening of anti-HCV agents
CN113293179A (zh) 一种靶向敲除HBx蛋白的质粒及其构建方法和应用
KR20220114504A (ko) 내열성이 개선된 뉴캐슬병 바이러스 및 이를 포함하는 뉴캐슬병 바이러스 백신